Tune in to an Interview with Keynote David Meeker, Pres & CEO, Genzyme

Having trouble viewing this email? Click here

This is the Only Event Where You'll Have Direct Access to Renowned Thought Leaders in a Uniquely Collegial Setting
This boutique meeting will offer plenty of opportunities to engage with industry thought leaders, partners, clients, and colleagues to discuss critical issues facing the life sciences industry. From headlining topics, such as the recent Supreme Court ruling and the America Invents Act, to ongoing industry concerns, you'll learn about new developments and strategies to help you navigate the increasingly challenging marketplace.
Listen to an Interview with Keynote David Meeker, President & CEO of Genzyme
Click here to listen to this interview by Meeting Chair Mark Nawacki, where Dr. Meeker offers an inside look at how his company has leveraged strategic licensing and provides a preview of what we can expect at his talk in Boston next month. Share this interview with your colleagues, and visit www.LES2012spring.org for full program information and to register.
Register by Monday, April 30 for your last chance to save!
Don't Miss these Highlighted Sessions on How Recent Court Decisions and Legislative Updates Will Affect You:
New Hot Topic Workshop: The Now Uncertain Future of Personalized Medicine and Life Sciences Innovation  In this unanimous decision, the Supreme Court of the United States departed from its long-standing precedent that section 101 of the patent statute should be interpreted broadly in favor of patent eligibility. Instead, the Supreme Court appears to have conflated 35 U.S.C. § 102, which requires patent claims to be novel, and 35 U.S.C. § 103, requiring claims to be nonobvious, into the patent eligibility analysis under § 101 and held that Prometheus' dosing process is not eligible for patent protection because the process is effectively an unpatentable law of nature. In this workshop, we will evaluate the effects this decision may have on licensing personalized medicine and life sciences innovations. Maximizing the Value of Corporate Intellectual Property Assets Following Enactment of the America Invents Act The Leahy-Smith America Invents Act (AIA) signed into law on September 16, 2011, makes numerous changes to U.S. patent law and USPTO practice. These changes necessitate a reevaluation of business strategies for patent prosecution, litigation, and technology transfer. This discussion will highlight practical considerations for in-house counsel and technology transfer professionals in view of the AIA. Topics to be considered include provisions of the AIA that potentially affect practices for internal invention review, patent prosecution, litigation, and collaboration and license agreements. Click here for the full program information, including additional workshop options, plenary sessions and networking opportunities.
Gold Sponsors Silver Sponsors             Bronze Sponsors                         Museum of Fine Arts Networking Reception          Official Strategic Media Partner Media Partners                             Supporting Organizations

© 2012 Licensing Executives Society (U.S.A. and Canada), Inc. All rights reserved.

Forward email This email was sent to seth.t.chase@gmail.com by lesmeetings@les.org |   Update Profile/Email Address | Instant removal with SafeUnsubscribe™ | Privacy Policy. LES (USA & Canada) | 1800 Diagonal Road | Suite 280 | Alexandria | VA | 22314